Cited 0 times in
XaMINA: A Real-World, Prospective, Observational Study of Treatment-Naïve Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation in Asia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이문형 | - |
dc.date.accessioned | 2022-08-23T00:33:07Z | - |
dc.date.available | 2022-08-23T00:33:07Z | - |
dc.date.issued | 2022-07 | - |
dc.identifier.issn | 0741-238X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/189491 | - |
dc.description.abstract | Introduction: The efficacy and safety of rivaroxaban for the prevention of stroke and systemic embolism have been demonstrated in Asian and non-Asian patients with non-valvular atrial fibrillation (NVAF) in multiple studies. However, limited published data exist on its use specifically in treatment-naïve patients from the Asia region. Patients in South Korea and Taiwan can now receive rivaroxaban as first-line therapy, allowing for data generation in this patient group. Methods: XaMINA was a prospective, real-world, multicenter, single-arm, observational cohort study of patients with NVAF in South Korea and Taiwan naïve to anticoagulation and initiating rivaroxaban. The primary outcome was major bleeding; secondary outcomes included all-cause mortality, symptomatic thromboembolic events, and treatment persistence. Results: In total, 1094 patients were included and the follow-up was 1 year. The baseline mean CHADS2 score was 1.63 ± 0.98, mean CHA2DS2-VASc score was 2.92 ± 1.42, and mean HAS-BLED score was 1.00 ± 0.75. The primary outcome occurred in 20 (1.8%) patients [incidence rate 2.1 events per 100 patient-years (95% CI 1.35-3.25)]. Thromboembolic events occurred in 9 (0.8%) patients, of whom 5 (0.5%) had stroke, 3 (0.3%) myocardial infarction, and 1 (0.1%) a transient ischemic attack. There were no cases of non-central nervous system systemic embolism, and 735 (67.2%) patients persisted with rivaroxaban treatment for 1 year. Conclusion: XaMINA demonstrated low incidence rates of major bleeding events and thromboembolic events in patients with NVAF newly initiating rivaroxaban in South Korea and Taiwan, consistent with previous real-world studies reconfirming the results of the ROCKET AF study. Trial registration: The trial was registered on ClinicalTrials.gov (identifier NCT03284762) on 15 September 2017. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Health Communications | - |
dc.relation.isPartOf | ADVANCES IN THERAPY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Anticoagulants / adverse effects | - |
dc.subject.MESH | Atrial Fibrillation* / complications | - |
dc.subject.MESH | Atrial Fibrillation* / drug therapy | - |
dc.subject.MESH | Embolism* | - |
dc.subject.MESH | Factor Xa Inhibitors / adverse effects | - |
dc.subject.MESH | Hemorrhage / chemically induced | - |
dc.subject.MESH | Hemorrhage / epidemiology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Rivaroxaban / adverse effects | - |
dc.subject.MESH | Stroke* / epidemiology | - |
dc.subject.MESH | Stroke* / etiology | - |
dc.subject.MESH | Stroke* / prevention & control | - |
dc.subject.MESH | Thromboembolism* / chemically induced | - |
dc.subject.MESH | Thromboembolism* / prevention & control | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | XaMINA: A Real-World, Prospective, Observational Study of Treatment-Naïve Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation in Asia | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Ping-Yen Liu | - |
dc.contributor.googleauthor | Eue-Keun Choi | - |
dc.contributor.googleauthor | Tae-Seok Kim | - |
dc.contributor.googleauthor | Jen-Yuan Kuo | - |
dc.contributor.googleauthor | Jung Myung Lee | - |
dc.contributor.googleauthor | Young Keun On | - |
dc.contributor.googleauthor | Sang-Weon Park | - |
dc.contributor.googleauthor | Hyung-Wook Park | - |
dc.contributor.googleauthor | Dong-Gu Shin | - |
dc.contributor.googleauthor | Lili Wang | - |
dc.contributor.googleauthor | Hsueh-Wei Yen | - |
dc.contributor.googleauthor | Moon-Hyoung Lee | - |
dc.contributor.googleauthor | XaMINA Investigators | - |
dc.identifier.doi | 10.1007/s12325-022-02102-8 | - |
dc.contributor.localId | A02766 | - |
dc.relation.journalcode | J00048 | - |
dc.identifier.eissn | 1865-8652 | - |
dc.identifier.pmid | 35616848 | - |
dc.identifier.url | https://link.springer.com/article/10.1007/s12325-022-02102-8 | - |
dc.subject.keyword | Atrial fibrillation | - |
dc.subject.keyword | Direct oral anticoagulant | - |
dc.subject.keyword | Non-vitamin K antagonist oral anticoagulant | - |
dc.subject.keyword | Real-world evidence | - |
dc.subject.keyword | Rivaroxaban | - |
dc.subject.keyword | Stroke | - |
dc.subject.keyword | Thrombosis | - |
dc.contributor.alternativeName | Lee, Moon-Hyoung | - |
dc.contributor.affiliatedAuthor | 이문형 | - |
dc.citation.volume | 39 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 3316 | - |
dc.citation.endPage | 3333 | - |
dc.identifier.bibliographicCitation | ADVANCES IN THERAPY, Vol.39(7) : 3316-3333, 2022-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.